In today’s briefing:
- Pre-IPO Zephyrm Bioscience – Despite Promising Pipeline, Investment Risk Is High

Pre-IPO Zephyrm Bioscience – Despite Promising Pipeline, Investment Risk Is High
- There’s great potential for PSCs, which provides new treatment options for complex diseases where traditional therapies are ineffective.The more solid the platform technology, the greater the dividends in later stage.
- Zephyrm’s pipeline candidates are promising. However, considering the R&D risks, the uncertainty of future commercialization and product safety profile, we think the investment risk of this Company is relatively high.
- Valuation of overseas peers is not high. In our view, valuation performance of Zephyrm would be largely depend on its clinical results of pipeline, which is a gamble for investors.